Evidence map›Paper›PMID 37392339›Full record

ArticleAdvances in therapy2023

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients.

Pierre Pommerolle, Pierre Laurent, Claire Presne, François Brazier, Maïté Jaureguy, Coralie Poulain, Gauthier Flahaut, Hakim Mazouz, Etienne Brochot, Gabriel Choukroun and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Pierre PommerolleNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France. pommerolle.pierre@chu-amiens.fr.ORCID http://orcid.org/0000-0003-2307-9981
Pierre LaurentNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Claire PresneNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
François BrazierNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Maïté JaureguyNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Coralie PoulainNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Gauthier FlahautNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Hakim MazouzNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Etienne BrochotVirology Department, Amiens University Hospital, 80000, Amiens, France.
Gabriel ChoukrounNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Ophélie FourdinierNephrology Dialysis Transplantation Department, Amiens University Hospital, 80000, Amiens, France.
Centre Hospitalier Universitaire Amiens-Picardie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionKidney transplant recipients (KTRs) produce a weak humoral response to coronavirus disease 2019 (COVID-19) vaccines. However, the factors associated with the quality of the serological response to three doses of COVID-19 vaccine have not been unambiguously identified.

methodsWe included KTRs followed in the Nephrology Department at Amiens University Hospital (Amiens, France) between June and December 2021 who had received three doses of a COVID-19 mRNA vaccine (or two doses plus an episode of polymerase chain reaction-confirmed COVID-19). The lack of a humoral response was defined as an antibody titer below 7.1 binding antibody units (BAU)/mL, and an optimal response was defined as an antibody titer above 264 BAU/mL.

resultsOf the 371 patients included, 246 (66.3%) were seropositive, and 97 (26.1%) had an optimal response. In a multivariate analysis, the only factor associated with seropositivity was a history of COVID-19 [odds ratio (OR) 87.2; 95% confidence interval (CI) (7.88-965.0); p < 0.0001], while the main factors associated with non-response were female sex [OR 0.28; 95%CI (0.15-0.51); p < 0.0001], less than 36 months between kidney transplantation and vaccination [OR 0.26; 95%CI (0.13-0.52); p < 0.0001], a higher creatinine level [OR 0.33; 95%CI (0.19-0.56); p < 0.0001], the use of tacrolimus [OR 0.23; 95%CI (0.12-0.45); p < 0.0001], the use of belatacept [OR 0.01; 95%CI (0.001-0.20); p = 0.002] and three-drug immunosuppression [OR 0.39; 95%CI (0.19-0.78); p = 0.015]. A history of COVID-19 was associated with an optimal response [OR 4.03; 95%CI (2.09-7.79); p < 0.0001], while an older age at vaccination [OR 0.97; 95%CI (0.95-0.99); p = 0.002], less than 36 months between kidney transplantation and vaccination [OR 0.35; 95%CI (0.18-0.69); p = 0.002], a higher creatinine level [OR 0.60; 95%CI (0.38-0.93); p = 0.02], three-drug immunosuppression [OR 0.45; 95%CI (0.27-0.76); p = 0.003] were associated with a poorer response.

conclusionWe identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs.

Indexed as

COVID-19Kidney TransplantationCOVID-19 VaccinesCreatinineFemaleHumansMalemRNA VaccinesCOVID-19 VaccinesCreatininemRNA VaccinesCOVID-19Humoral responseKidney transplantationmRNA vaccineSARS-CoV-2

Identifiers

PMID37392339
OpenAlexW4382810998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.